ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Cash from Financing Activities data on file, last reported at $159000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 78.07% year-over-year to $159000.0; the trailing twelve-month figure through Mar 2026 stood at $104.0 million (up 42.77% YoY), and the FY2025 full-year result was $104.6 million, up 44.47% from the prior year.
• Cash from Financing Activities fell to $159000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $193.8 million in Q4 2022 to a low of -$1.6 million in Q3 2022.
• A 5-year average of $22.0 million and a median of $921000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 1151.35% in 2022 and soared 14612.5% in 2025, its largest moves.
• Tracing SPRY's Cash from Financing Activities over 5 years: stood at $193.8 million in 2022, then sank by 99.07% to $1.8 million in 2023, then soared by 3828.86% to $70.9 million in 2024, then tumbled by 98.41% to $1.1 million in 2025, then tumbled by 85.94% to $159000.0 in 2026.
• Business Quant data shows SPRY's Cash from Financing Activities at $159000.0 in Q1 2026, $1.1 million in Q4 2025, and $100.0 million in Q3 2025.